Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
To all you chart/trading experts out there. What IYO is causing the unusually wide spread on B/A and the highly volatile moves on minuscule volume?
I'd rather news not come out. The only news that will help here is substantial revenue increase from an unknown patent deal or QuadraMune distribution deal. Anything else will just be sucked into a black hole like the form 4's and accelerate the selling out of frustration. The CEO sees the pps is under attack. He is doing his job to make sure this is done CORRECTLY. He has hinted at " very good news" that's in the works. Our job now is to wait, be patient and reap the benefits. We need to stop setting unverifiable timelines for news, pps rises. Chart interpretations thought the day. This is Not a normal situation and will not have a " normal " outcome because we are in the to have an Exponentially successful return on our investments.That takes time and preparation. The "whales" we want want verification this is real. The CEO WILL DELIVER when the company is ready. And not before. See you at the bank!!!
Pssst.. don't date them say " they are too scared to let this break $.10
??????
? New news? I can't find them
Everything i said was fact. I asked you why you your reason for disputing what i said .
How do you explain it then? No solid financial reason drove this price from the subs. It was not news of the trial or the form 4's . Neither occured of the day of the move. Covid 19 speculators did based on sentiment. Today news was released on a possible steroid "treatment " but NOT a prophylactic. Maybe this in some minds changed the game. Even though hospitals are filling up again and states acting like it has disappeared. Time will tell
Seems MM's have taken the stance that TSOI is venerable until trials for
QuadraMune are successful. They will short and swing this until either positive profits show up to justify price or buyout offer. We WILL get there, but a lot will not be able to stand the psychological whiplash of the ticker every day.
So... float went -DOWN?
HOLD THE LINE!!
This has been discussed to the point of nauseam. Can we please move on from the form4 discussion? We get it. It affects NOTHING except for sentiment. The shares are restricted and does not affect float or price. So can we move on now? Thanks.
You know, absolutely despise Monday morning quarterbacking . The CEO took immediate action to squash the PR PERIOD. Some act as if he knew this was coming and should have been prepared for it. Its like being awaken in the middle of the night by a burglar in your house and the next day you're complaining someone used a knife instead of a gun and got blood on your carpet. He did his job. He corrected the action and now its in the hand of the authorities. Good grief.
I think the fact that someone went to the extent of falsifying a company press release to damage the companies share price, and the "irregular " trading we saw today is not coincidental. You release a "NOT US" validated pr, Not one, but TWO form 4's and another press release of filing a NEW possibly BILLION dollar patent, and the price falls? Someone with a vested interest here is highly motivated to keep this price down.
Say my name..SAY IT!! "Parabolic baby!!"
BOOOOOMM$$
HAHAHA very funny. Dilution? A form 4 does not issue shares, it restricts them from sale for 6 months. Hence "locking". If you were correct price would DROP. Yet it INCREASES with each form 4. SQUEEZE
Insiders ate are purchasing a SERIOUS percentage of the float. They are definitely sending a message.
Yes you did!! The CEO an insiders obviously prepared for manipulation and was monitoring trading activity. The are launching form 4 trident warheads at them backed up with patent thermonuclear Pr's. No way they hold this down for long!
Therapeutic Solutions International Reports Reduction of Brain Inflammation/Depression Associated Biochemical Pathway
Source: InvestorsHub NewsWire
?
Therapeutic Solutions International Reports Reduction of Brain Inflammation/Depression Associated Biochemical Pathway Using QuadraMune™ in Animal Studies
Continued Basic Science Experiments Support New Patent Filing Covering Suppression of Indolamine 2,3 Deoxygenase Pathway by QuadraMune™
OCEANSIDE, CA -- June 15, 2020 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the filing of a new patent covering suppression of the indolamine 2,3 deoxygenase (IDO) pathway by QuadraMune™ administration.
In the study, mice were administered lipopolysaccharide (LPS), a compound known to stimulate inflammation, in order to replicate inflammation-associated depression. Mice receiving LPS suffered a reduction in memory activity, as quantified using the Morris Water Maze test.
Administration of QuadraMune™ significantly inhibited inflammation associated with memory impairment, as well as reduced levels of kynurenine. Elevation of kynurenine is associated with activation of indolamine 2,3 deoxygenase, an enzyme associated with inflammation and depression [1].
"The current data support the possibility of QuadraMune™ being used as an adjuvant to numerous immune therapies whose efficacy is currently inhibited by the depression-inducing and immune blocking effects of the indolamine 2,3 deoxygenase enzyme," said Dr. James Veltmeyer, Chief Medical Officer and co-inventor of the current patent. "Many times, when you activate the immune system, cells in the body, and in the brain, start producing the enzyme indolamine 2,3 deoxygenase, whose role is to restrain the immune system, and for reasons unknown, causes depression. By manipulating this enzyme through natural means, we are optimistic that we can enhance the efficacy of numerous immune modulatory treatments for viral and neoplastic conditions."
Dr. Thomas Ichim, Board Member of Therapeutic Solutions International, has been working on this enzyme since 2013 when he published in the peer-reviewed literature regression of breast cancer using RNA interference to block its expression [2].
"From a commercialization perspective we are truly optimistic about the implications of the current results, which may require us to consider expanding our clinical trial programs," said Timothy Dixon, President, and CEO of the Company. "The IDO enzymatic pathway is not only extremely interesting from a medical perspective, but companies working on manipulating this pathway have previously entered Big Pharma deals with potential values in excess of $1 billion [3]. In contrast to other programs that utilize synthetic approaches, QuadraMune™, which is comprised of natural ingredients and is available as a nutraceutical, may possess numerous advantages for accelerated commercialization."
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is at www.therapeuticsolutionsint.com and our e-commerce is at www.youcanordernow.com and for additional info on QuadraMune™ visit www.areyoucovidmune.com/covidmune/.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
[1] Lanser et al. Inflammation-Induced Tryptophan Breakdown Is Related With Anemia, Fatigue, and Depression in Cancer. Front Immunol . 2020 Feb 21;11:249. https://www.frontiersin.org/articles/10.3389/fimmu.2020.00249/full
[2] Zheng et al. Silencing IDO in Dendritic Cells: A Novel Approach to Enhance Cancer Immunotherapy in a Murine Breast Cancer Model. Int J Cancer. 2013 Feb 15;132(4):967-77
[3] https://news.bms.com/press-release/rd-news/bristol-myers-squibb-expand-its-immuno-oncology-pipeline-agreement-acquire-fle
Therapeutic Solutions International, Inc.
ir@tsoimail.com
Company Files New Patent Application on QuadraMune™ for Suppression of Indolamine 2,3 Deoxygenase Pathway
News it OUT!!
Money aside..pray this drug saves lives
Say my name SAY IT!parabolic baby!!
PENNYLAND!!! CONGRATULATIONS ALL!!
BOOOOMMMM!!!!
Low down dirty painted close
They goona try and touch the .002's
Volatility is high relative to light volume. This thing is wound tight. Any news and all bets are off.
Correct!
Ask very strong this morning
There seems to be some confusion about the 10k release
$INQD 10K should be out by May 30th, but, being a Saturday, it could come out tomorrow:
NT-10K was filed on May 15th, giving the company an extra 15 days ----------->May 30th, 2020
before extension it was stated by company that 10k would be filed within 45 days of March 30'th, which puts us at tomorrow ( 30th being weekend). thoughts?
Ok, here we go.up to .70 cor close
Congrats everyone. Thanks to all who contributed valuable DD.
Let's get to copperland!